i-Path announces partnership agreement with iSOFTGroup Ltd August 11, 2010
i-Path have announced an agreement with iSOFT Group Ltd. which will significantly boost iSOFT’s ability to deliver modern digital pathology solutions to its existing customers and the wider pathology market.
PathXL used in GlaxoSmithKline Lung Cancer Trials August 10, 2010
GlaxoSmithKline is developing ASCI, a type of cancer immunotherapy, as a potential new treatment for certain types of lung cancer. It is currently being tested in two large clinical trial involving thousands of non-small cell lung cancer patients.